![]() |
市场调查报告书
商品编码
1304546
全球高压氧治疗市场 - 2023-2030年Global Hyperbaric Oxygen Therapy Market - 2023-2030 |
※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。
全球高压氧治疗市场规模在2022年达到32亿美元,预计到2030年将达到67亿美元,实现利润丰厚的增长。在预测期内(2023-2030年),全球高压氧治疗市场预计将呈现9.9%的复合年增长率。技术的不断进步和对新型产品投资的不断增长推动了高压氧治疗市场需求的发展趋势。
高压氧治疗是动脉气体栓塞和减压病的唯一公认治疗方法。正如波义耳定律所预测的那样,在加压过程中(也称为高压氧治疗的压缩阶段),体内含气腔会发生收缩,这有助于减少气泡并缓解组织或血管内区域的压力。新产品的推出和伤口愈合率的上升是推动全球高压氧治疗市场发展的主要因素。
高压氧疗法的市场范围包括糖尿病足溃疡、伤口愈合、减压病、感染治疗、气体栓塞等应用,这增加了高压氧疗法的市场份额。全球高压氧治疗市场正在不断扩大,其原因包括各国不断加大研发力度,即将批准的新型产品也为高压氧治疗市场的增长创造了积极的前景。
高压氧疗法利用道尔顿定律和亨利定律分别提高肺泡-血浆梯度和氧溶解度。用数学方法来说明这一点,在3 ATA下给予100%的氧气,可使组织和动脉血氧张力分别提高500和2000 mmHg,从而可提供6 mL O2/dL。
显而易见,HBOT后,血浆携带溶解氧的能力足以在没有血红蛋白辅助的情况下维持体内平衡。因此,即使在血红蛋白氧运输受阻的情况下,如一氧化碳中毒和严重贫血,血浆中的氧仍可输送到组织中。
与血红蛋白相比,使用血浆输送氧气的另一个好处是,血浆可以到达红细胞因物理障碍(如血栓或闭塞)而无法到达的地方。这些优势是推动高压氧治疗市场增长的主要因素。
高压氧的潜在临床益处正在许多不同的领域得到研究。研究范围包括老年病和中风。此外,还对运动损伤、高原病、脑损伤、认知功能、偏头痛、暴发性肝炎、脊髓损伤、闭合性颅脑损伤和镰状细胞危象进行了研究。
世界各地的多中心研究人员还在研究暴发性紫癜、放线菌病、肠系膜病、血栓形成、视网膜中央动脉闭塞、囊样黄斑水肿和麻风病。随机临床试验设计、安慰剂效应、霍桑效应、药代动力学和其他主题也在讨论之中。
由于缩短了住院时间和病程,成本分析表明,在常规治疗的基础上增加高压氧可显著节约成本。目前正在进行各种研究。
与所有医疗程序类似,高压氧治疗有利有弊。高浓度氧可导致氧化应激,从而损害细胞和组织,包括DNA。如果损伤未得到充分愈合,这有可能导致癌症,因为它会导致突变。然而,对科学文献的研究表明,尽管存在这种担忧,但绝大多数已发表的研究都没有发现这种影响。
快速的压力变化可导致中耳、颅窦或(极少数情况下)牙齿或肺部破裂,给患者带来轻微至剧烈的疼痛。通过对患者进行降低风险技术(如自动充气技术)的教育,可以避免这种情况的发生。尽管HBOT可治疗的疾病和失调范围不断扩大,但在美国仍存在一些限制。
一次90分钟的疗程一般在300至400美元之间,因此HBOT的价格相当昂贵。因此,30-40次治疗的价格在9,000-16,000美元之间。然而,与院内非高压氧治疗相比,对患有骨坏死的患者进行高压氧治疗的经济分析表明可节省96,000美元。
COVID-19疫情和全球封锁对各行各业的企业财务健康都产生了影响。因此,美国食品和药物管理局(FDA)发布了COVID-19卫生紧急状态期间的指导方针,其中包括协助申办者和研究人员、确保试验参与者安全、遵循良好临床实践(GCP)以及降低试验完整性风险的一般注意事项。
据估计,俄乌冲突对全球高压氧治疗市场的影响较小,因为该地区的主要市场参与者较少。然而,原材料进出口的影响预计在预测期内对全球高压氧治疗市场的增长影响不大。
The Global Hyperbaric Oxygen Therapy Market size reached US$ 3.2 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 6.7 billion by 2030. The global hyperbaric oxygen therapy market is expected to exhibit a CAGR of 9.9% during the forecast period (2023-2030). The increasing technological advancements and the growing investments in novel products are driving up demand for hyperbaric oxygen therapy market trends.
The only accepted treatment for arterial gas embolism and decompression sickness is HBOT. As predicted by Boyle's law, a contraction takes place in the body's gas-containing cavities during pressurization, also referred to as the compression phase of HBOT, which aids in reducing air bubbles and relieving pressure in the tissue or intravascular area. The launch of new products and an increase in the prevalence of wound healing are the main factors propelling the global market for hyperbaric oxygen therapy.
The hyperbaric oxygen therapy market scope comprises applications such as diabetic foot ulcers, wound healing, decompression sickness, infection treatment, gas embolism and others, which has increased the hyperbaric oxygen therapy market share. The global market for hyperbaric oxygen therapy is expanding as a result of factors including increasing research and development and their upcoming novel product approvals across countries are also creating a positive outlook for the hyperbaric oxygen therapy market growth.
Dalton's law and Henry's law are both utilized by hyperbaric oxygen therapy to boost the alveoli-plasma gradient and oxygen solubility, respectively. To illustrate this mathematically, giving 100% oxygen at 3 ATA raises tissue and arterial oxygen tension by 500 and 2000 mmHg, respectively, allowing for the delivery of 6 mL O2/dL.
Evidently, after HBOT, the plasma's ability to carry dissolved oxygen is sufficient to sustain homeostasis without the aid of hemoglobin. As a result, even in conditions where hemoglobin oxygen transport is impeded, like carbon monoxide poisoning and severe anemia, this oxygen can still be delivered to tissues.
Another benefit of employing plasma to deliver oxygen over hemoglobin is that it can get to places where red blood cells can't because of physical obstructions (such clots or occlusions). These advantages are the major factor that will help in driving the growth of the hyperbaric oxygen therapy market.
The potential clinical benefits of hyperbaric oxygen are being investigated in a number of different contexts. Investigated are senility and strokes. Research is also being done on sports injuries, high altitude sickness, brain injuries, cognitive functions, migraines, fulminant hepatitis, Spinal cord injury, closed head injury, and sickle cell crisis.
Workers in multicentric studies around the world are also investigating purpura fulminans, actinomycosis, mesenteric, thrombosis, central retinal artery occlusion, cystoid macular edema, and leprosy. Randomized clinical trial designs, the placebo effect, the Hawthorne effect, pharmacokinetics, and other topics are also being discussed.
Due to shorter hospital stays and shorter illness duration, cost analysis has demonstrated that adding hyperbaric oxygen to conventional treatment yields significant cost savings. Various kinds of research are being done.
Similar to every medical procedure, treatment has advantages and disadvantages. High oxygen concentrations can lead to oxidative stress, which can damage cells and tissues, including DNA. This has the potential to cause cancer if the damage is not sufficiently healed since it can result in mutations. An examination of the scientific literature, however, revealed that, in spite of this worry, the vast majority of published investigations had failed to find such an effect.
Rapid pressure shifts can cause the middle ear, cranial sinuses, or (rarely) the teeth or lungs to rupture, causing mild to severe pain in the patient. By educating the patient about risk reduction techniques like the auto inflation technique, this can be prevented. Despite the expanding range of illnesses and disorders that HBOT can treat, there are still some restrictions in place in the United States.
With a typical 90-minute session ranging between $300 and $400, HBOT is rather pricey. Therefore, the price of 30-40 sessions can range from $9,000-16,000. However, compared to in-hospital, nonhyperbaric oxygen therapy, an economic analysis of hyperbaric oxygen therapy for individuals with osteoradionecrosis revealed a savings of $96,000.
The COVID-19 epidemic and the worldwide lockdown have had an effect on the financial health of businesses in all industries. As a result, the U.S. Food and Drug Administration (FDA) released guidelines for the duration of the COVID-19 health emergency that include general considerations to assist sponsors and researchers, ensure trial participants' safety, follow good clinical practice (GCP), and reduce risks to trial integrity.
The Russia-Ukraine conflict is estimated to have a low impact on the global hyperbaric oxygen therapy market, owing to the low number of key market players in this region. However, the impact of the import and export of raw materials is expected to have little influence over the global hyperbaric oxygen therapy market growth over the forecast period.
The global hyperbaric oxygen therapy market is segmented based on product type, application, end user and region.
Hemostasis, the elimination of infectious agents, the resolution of the inflammatory response, the development of a connective tissue matrix, and resurfacing are all stages of the normal wound healing process, which is a positive feedback system. Chronic wounds are ones that do not fully heal as a result of an internal or external issue that arises throughout one or more stages of the healing process.
These include arterial ulcers, pressure ulcers, venous stasis ulcers, and diabetic wounds. The most frequent causes of wound healing delays are infection and ischemia, both of which are characterized by hypoxia. The infection triggers an overly aggressive response during the inflammatory stage of wound healing, which leads to a quick loss of oxygen in the tissue and inadequate blood flow because of edema.
By boosting the blood's oxygen content and creating a conducive gradient for oxygen diffusion into the injured tissues, hyperbaric oxygen therapy promotes the healing process. Since fibroblast proliferation, angiogenesis, collagen synthesis, and infection resistance are oxygen-dependent activities, enough oxygen is crucial for healing. HBOT has also been demonstrated to control inflammation by generating reactive oxygen species.
Manufacturers have chances to expand their operations in this region because of the rising demand for hyperbaric oxygen therapy for advancements in North America. The area has many producers and suppliers, and its rapid economic development has raised the industrial production of hyperbaric oxygen chambers, which has increased the demand.
There are many manufacturers and suppliers in North America, and as a result of the region's rapid economic growth, industrial production has expanded, feeding the desire for research and development of novel products.
The market will grow as new technology for research and development emerge. Rising technological developments, governmental approvals, and the introduction of new products all contribute to growth. People are becoming more aware of novel wound healing therapies or chambers, leading to the expansion of the market in this region. These factors are responsible for dominance of North America.
The major global players in the hyperbaric oxygen therapy market include: Environmental Tectonics Corporation, Sosgroup, HEARMEC, Gulf Coast Hyperbarics Inc., Tekna Hyperbaric, Perry Baromedical, Hpotech Hyperbaric Solutions, Haux Life Support, Sechrist Industries, Inc and Royal IHC among others.
The global hyperbaric oxygen therapy market report would provide approximately 53 tables, 54 figures and 195 Pages.
Australia
LIST NOT EXHAUSTIVE